MedMira Receives Patent for Rapid Test Technology - European Patent Office Allows Newest Generation Multiplo Test Platform



    HALIFAX, NS, June 19 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ:   MMIRF), a global market leader in premium rapid diagnostic solutions,
announced today that it has received an "Intent to Grant Notice" (the European
equivalent of the United States Notice of Allowance) from the European Patent
Office for its rapid diagnostic device and assay (European Patent
Application No. 02 753 996.4). The novel invention is the core technology in
MedMira's line of rapid diagnostic tests and the basis for its newest
generation Multiplo(TM) platform, which can simultaneously detect multiple
disease markers in minutes. The Multiplo(TM) Rapid HBV/HIV/HCV Antibody Test
recently received regulatory approval from the Ministry of Health in the
Russian Federation.
    The patented technology, an innovative rapid flow-through diagnostic
device, assay, and multifunctional buffer reagent, provides users the ability
to detect multiple target analytes in a single sample, using the materials
provided, in just three minutes. Therefore, critical answers are delivered
when time really matters.
    "Receiving this patent is key to MedMira's ability to further capitalize
on its unique offering of truly rapid, and high quality test technology," said
Hermes Chan, President and CEO of MedMira. "Simultaneous multiple disease
detection is the next step in streamlining diagnostics, and enabling health
care providers to deliver quality diagnostic results quickly and easily."
    MedMira had formally introduced this technology using its Multiplo(TM)
Test for HIV and Hepatitis at the XVI International AIDS Conference in
Toronto, Ontario in August 2006. Moving forward, MedMira aims to develop
additional tests in the Multiplo family and seek key approvals in the global
market.
    Chan continued, "As we move our efforts forward in developing innovative
diagnostic devices, having patent protection for our technology is not only
important, but it allows us to effectively seek new licensing opportunities.
This fits in with our strategic goals for our technology and for MedMira as a
whole."

    About MedMira

    MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics. The company's tests provide hospitals, labs, clinics and
individuals around the world with reliable, rapid diagnosis for diseases such
as HIV and hepatitis C in just three minutes. The company's tests are sold
under the Reveal(R), MiraWell(R), MiraCare(TM) and Multiplo(TM) brands in
global markets. MedMira's rapid HIV test is the only one in the world to
achieve regulatory approvals in Canada, the United States, China and the
European Union.
    In January 2006, MedMira launched the Maple Biosciences division to
develop and commercialize diagnostic instruments based on two revolutionary
biosensor-based technology platforms. The solutions developed by Maple
Biosciences will enable routine laboratory tests to be performed in a matter
of minutes, increasing laboratory automation, streamlining the diagnosis of
multiple conditions and diseases and positioning MedMira to be a leading
participant in the emerging fields of personalized medicine and molecular
diagnostics. For more information visit www.maplebio.com.
    MedMira's corporate offices and manufacturing facilities are located in
Halifax, Nova Scotia, Canada with a representative office in China. Maples
Biosciences' labs are located in Toronto, Ontario. For more information visit
MedMira's website at www.medmira.com.

    This news release contains forward-looking statements, which involve risk
and uncertainties and reflect the company's current expectation regarding
future events. Actual events could materially differ from those projected
herein and depend on a number of factors including, but not limited to,
changing market conditions, successful and timely completion of clinical
studies, uncertainties related to the regulatory approval process,
establishment of corporate alliances and other risks detailed from time to
time in the company quarterly filings.

    The TSX Venture Exchange has not reviewed and does not accept
    responsibility for the adequacy or accuracy of this statement.
    %SEDAR: 00013053E




For further information:

For further information: Dr. James Smith, Investor Relations & Corporate
Affairs, (902) 450-1588, ir@medmira.com

Organization Profile

MedMira Inc.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890